CHRONIC HEPATITIS B

This study tests whether combining two drugs—ASC22 and pegylated interferon alfa—can functionally cure chronic hepatitis B. It involves 150 adults with low virus levels and no hepatitis B e-antigen. The goal is to raise the cure rate above 50% without needing to select specific p…

This study tests a new combination of drugs to achieve a functional cure for chronic hepatitis B, meaning the virus is controlled without lifelong medication. About 120 adults with chronic hepatitis B will receive an immune-boosting drug (anti-PD-1 antibody) along with standard a…

This early-stage study tests a new injection called SA1211 in healthy people and those with chronic hepatitis B. The goal is to check if it is safe and tolerable, and to see early signs of whether it can help control the virus. About 80 participants will receive either the inject…

This study tests a new combination of drugs (anti-PD-1 antibody and interferon) to help the immune system clear the hepatitis B virus from the body. The goal is to achieve a 'functional cure,' meaning the virus is no longer active and the patient can stop long-term medication. Ab…

This early-stage study tests whether HEPLISAV-B, a vaccine normally used to prevent hepatitis B, is safe in people who already have chronic hepatitis B. Ten adults on antiviral therapy will receive two vaccine shots and be monitored for side effects and immune responses over 14 m…

This study looks at how the drug TAF works in pregnant women with chronic hepatitis B. The goal is to see if it is safe for both mother and baby and if it can reduce the chance of passing the virus to the infant. About 50 women between 20 and 40 years old will take TAF during lat…

This study tests an experimental injection called HRS-5635, given alone or with other drugs, in 369 adults with chronic hepatitis B whose virus is already suppressed by standard pills. The main goal is to lower or clear a key virus marker (HBsAg) from the blood. Participants must…

This study tests whether tenofovir alafenamide (TAF) is safe and effective for children and teens with chronic hepatitis B. About 150 participants will receive either TAF or a placebo. The goal is to see if TAF can lower the virus level in the blood with fewer side effects than c…

This study checks if people with chronic hepatitis B who got better with the drug AHB-137 stay virus-free over time. Researchers will follow 200 participants for years to see if the virus stays undetectable. The goal is to understand how long the treatment effect lasts.

This phase 3 trial tests a new drug called GST-HG141 (Neracorvir) added to standard antiviral pills for people with chronic hepatitis B who still have virus in their blood despite treatment. About 526 adults aged 18-70 who have been on antivirals for over a year will receive eith…

This study tests an experimental injection called AHB-137 in 60 adults with chronic hepatitis B who have already been treated with standard antiviral pills. The goal is to see if the injection can clear the hepatitis B surface antigen and keep the virus undetectable after stoppin…

This study tests whether dapagliflozin, a diabetes drug, can prevent serious liver complications like liver cancer or liver failure in people with chronic hepatitis B and diabetes. About 412 participants will take either the drug or a placebo daily for up to 5 years. The goal is …

This study tests a new drug called AHB-137 given with either a hepatitis B vaccine or another medicine (pegylated interferon) in people with chronic hepatitis B who are already on standard antiviral pills. The goal is to see if the combination can lower the virus to undetectable …

This study looks at whether adding a specific gut bacteria (Bacteroides fragilis) and branched-chain amino acids to standard hepatitis B treatment can help clear the virus. Researchers will compare 40 chronic hepatitis B patients getting the combo with a control group on standard…

This study tests a drug called Imdusiran in 10 people with chronic hepatitis B. Participants get 4 injections over 8 months and have two liver biopsies to see how the drug works inside the liver and how it affects the virus. The goal is to understand the drug's action better, not…

This study tests azvudine tablets in 120 people with chronic hepatitis B to see if the drug can control the virus long-term. The approach combines antiviral action with immune system activation. Participants take the pill daily for 12 months, and researchers monitor viral levels,…

This early-stage study tests a new drug, Tune-401, in 36 adults with chronic hepatitis B who are already on standard antiviral therapy. The main goal is to check the drug's safety and how the body processes it. Researchers hope Tune-401 may help control the virus better, but this…

This study involves over 16,000 people with chronic hepatitis B across three hospitals in China. The goal is to increase the number of patients referred to liver specialists and started on antiviral treatment. Researchers will also measure how treatment affects patients' quality …

This study tests whether combining two drugs, VIR-2218 and peginterferon alfa-2a, can lower hepatitis B virus levels in people with mild or inactive chronic infection. About 50 adults aged 18 to 65 will receive monthly VIR-2218 shots for 6 months and weekly peginterferon shots fo…

This study tests whether a mobile app called HBVCare can help people with chronic hepatitis B take their medication regularly and attend follow-up visits. About 70 adults in Vietnam will either use the app or receive standard care. After three months, researchers will compare how…

This study looks at whether magnetic resonance elastography (MRE), a special MRI that measures tissue stiffness, can accurately grade liver fibrosis (scarring) in people with chronic hepatitis B. Researchers will compare MRE results to standard liver biopsies in 600 adults. If su…

This study looks at why the hepatitis B virus (HBV) stays in the liver for so long, even with treatment. Researchers will use a gentle needle method (fine needle aspiration) to take small liver samples from 100 adults with chronic HBV. The goal is to learn how the virus and the i…

This study follows 33,000 adults with chronic hepatitis B to see how different antiviral treatments affect their health over 5 years. Researchers will compare drugs like entecavir and tenofovir, alone or with peginterferon, to find which best lowers liver cancer risk and helps cl…

This study looks at whether people with chronic hepatitis B who have undetectable virus levels in their blood also have undetectable virus in other body fluids like saliva or semen. If true, it could support the message that undetectable means untransmissible (U=U) for hepatitis …

This study will follow 15,000 adults with chronic hepatitis B across 200 hospitals in China. Researchers will look at how different treatments affect liver cancer rates and other health outcomes. The goal is to find the best ways to manage the disease and work toward a cure.